International Journal of Molecular Sciences· 2018Q1· Review
Emerging Roles of Vascular Cell Adhesion Molecule-1 (VCAM-1) in Immunological Disorders and Cancer
- 687citations
- Q1SCImago
- 2018year
Short summary
Vascular cell adhesion molecule-1 (VCAM-1), induced by TNFα, is emerging as a key player in immunological disorders and cancer progression, beyond its known role in leukocyte adhesion and migration.
AI-generated from the title and abstract; the full text is not read.
Key points
- VCAM-1 expression is induced by the pro-inflammatory cytokine TNFα.
- VCAM-1 facilitates inflammation-associated vascular adhesion and leukocyte migration.
- VCAM-1 is associated with the progression of immunological disorders such as rheumatoid arthritis and asthma.
- VCAM-1 is also linked to cancer progression.
- VCAM-1 is being explored as a novel therapeutic target.
AI-generated from the title and abstract; the full text is not read.
Abstract
Tumor necrosis factor alpha (TNFα) is a pro-inflammatory cytokine that triggers the expression of inflammatory molecules, including other cytokines and cell adhesion molecules. TNFα induces the expression of intercellular cell adhesion molecule-1 and vascular cell adhesion molecule-1 (VCAM-1). VCAM-1 was originally identified as a cell adhesion molecule that helps regulate inflammation-associated vascular adhesion and the transendothelial migration of leukocytes, such as macrophages and T cells. Recent evidence suggests that VCAM-1 is closely associated with the progression of various immunological disorders, including rheumatoid arthritis, asthma, transplant rejection, and cancer. This review covers the role and relevance of VCAM-1 in inflammation, and also highlights the emerging potential of VCAM-1 as a novel therapeutic target in immunological disorders and cancer.
The authors' abstract, as published at the source. International Journal of Molecular Sciences, 2018 · DOI ↗
Continue with a free account
Ask the paper: 3 free questions a day about this paper; save it, get its citation, new summaries every day for your field. Takeaways are Premium.
Continue free on the webSign in with Google or Apple; no card needed. You come back to this paper.
On your phone:
Field: Immunology and Allergy
Immunology and AllergyMedicine